NIO
NICOTINIC ACID
Find entries where: NIO
is present as a standalone ligand in 56 entries
as a non-polymer is covalently linked to polymer or other heterogen groups 16 entries
is present in a polymer sequence 2 entries
Chemical Component Summary | |
---|---|
Name | NICOTINIC ACID |
Identifiers | pyridine-3-carboxylic acid |
Formula | C6 H5 N O2 |
Molecular Weight | 123.109 |
Type | NON-POLYMER |
Isomeric SMILES | c1cc(cnc1)C(=O)O |
InChI | InChI=1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9) |
InChIKey | PVNIIMVLHYAWGP-UHFFFAOYSA-N |
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 14 |
Chiral Atom Count | 0 |
Bond Count | 14 |
Aromatic Bond Count | 6 |
Drug Info: DrugBank
DrugBank ID | DB00627 |
---|---|
Name | Niacin |
Groups |
|
Description | Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.[L7550,L7553,L7556,L7559,L7562,L7565] |
Synonyms |
|
Brand Names |
|
Indication | Niacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injections.[L7550,L7553,L7556,L7559] Niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemia.[L7562,L7565] It can also be used to reduce the risk of nonfatal myocardial infarctions in patients with a history of myocardial infarction and hyperlipidemia.[L7562,L7565] Niacin is also indicated with bile acid binding resins to treat atherosclerosis in patients with coronary artery disease and hyperlipidemia or to treat primary hyperlipidemia.[L7562,L7565] Finally niacin is indicated to treat severe hypertriglyceridemia.[L7562,L7565] |
Categories |
|
ATC-Code |
|
CAS number | 59-67-6 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Hydroxycarboxylic acid receptor 3 | MNRHHLQDHFLEIDKKNCCVFRDDFIAKVLPPVLGLEFIFGLLGNGLALW... | unknown | agonist |
Hydroxycarboxylic acid receptor 2 | MNRHHLQDHFLEIDKKNCCVFRDDFIVKVLPPVLGLEFIFGLLGNGLALW... | unknown | agonist |
Nicotinate-nucleotide pyrophosphorylase [carboxylating] | MDAEGLALLLPPVTLAALVDSWLREDCPGLNYAALVSGAGPSQAALWAKS... | unknown | binder |
Nicotinamide N-methyltransferase | MESGFTSKDTYLSHFNPRDYLEKYYKFGSRHSAESQILKHLLKNLFKIFC... | unknown | binder |
Cytochrome P450 2D6 | MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVD... | unknown | inhibitor |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL573 |
PubChem | 117629482, 938 |
ChEMBL | CHEMBL573 |
ChEBI | CHEBI:15940 |
CCDC/CSD | AWUDEB, NICOAC01, GADQEL |
COD | 2311082, 2311084 |